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1. Introduction 
1.1 Non-small-cell lung cancer (NSCLC) 
1.1.1 Incidence and mortality 
Lung cancer represents the second malignancy in men in occidental world, 
accounting for 21% of new cancer cases and 30% of total death for cancer.  
In the United States 200.000 new cases are roistered every year, with about 160.000 
death/year. In the European Union one lung cancer is registered every 100.000 
habitants, with 50 deaths. 
It has been calculated that one man of 9, and 1 woman of 36 develop a lung cancer 
in his lifespan. In our country, lung cancer in men, from 2006 to 2009, were more 
incident in the north regions (73,0 cases/100.000 habitants) respect to the central 
(64,7 cases/100.000 habitants) and the south one (65,7 cases/100.000 habitants). In 
women, the difference in incidence between north and south regions is more 
marked, with 22,0 cases/100.000 habitants in north regions, 18,4/100.000 habitants 
in middle regions and 13,8/100.000 habitants in the south. A modest decrease in 
lung cancer incidence was observed in men, in relation to a parallel decrease in the 
smoking habits (-2,0%/year from 1996 to 2010). As contrary an increase was 
observed in women (+2,5%/year from 1996 to 2010). 
Lung cancer represents the first cause of death in men (26% of total death) and the 
third cause in women (11% of total death). Also for mortality, from 1996 to 2010 a 
decrease in men (-2,0%/year) and a constant increase in women (+1,8%/year) were 
observed. 5% survival of lung cancer patients is unmodified in the last years, and is 
about 14% in men and 18% in women. 
 
1.1.2 Risk factors and prevention 
Cigarette smoke represents the most important risk factor for lung cancer, and it is 
considered to be responsible for 85% of observed cases. 
The relative risk is in tight relation with the number of smoked cigarette/die, with 
the duration of smoking (years) and the content of tar (1-6). The relative risk of 
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smokers with respect to non smokers is 14, whereas that of heavy smokers (more 
than 20 cigarette/die) is 20 times. For smokers who stopped smoking, the risk 
decrease in the follow 10-15 years. Regarding passive smoke, it has been stimated 
an increase of about 20-50% with respect to non smokers.   
Some substances are recognized as lung carcinogens (asbestos, chrome, arsenic, 
beryllium, vinyl cloride,  radon, etc) and they can potentiate their effect in presence 
of tobacco smoke. 
Air pollution represents another risk for lung cancer.   
 
1.1.3 Staging and TNM classification 
Staging is one of the most important components in the management of lung 
cancer. Accurate staging is important because it allows the clinician to predict 
prognosis and assign appropriate therapy and also provides a system that allows 
clinicians and researchers to stratify patients into reasonably homogenous groups so 
that treatment outcomes can be appropriately compared. Tumor staging is broadly 
broken down into clinical staging and pathologic staging. Clinical stage refers to 
the best prediction of lung cancer stage prior to the commencement of therapy. 
Pathologic stage refers to the best prediction of stage following pathologic analysis 
of the patient’s tumor, lymph nodes, and/or metastases and is usually applied 
following surgical resection or exploration. In common with most other solid 
malignancies, lung cancer staging is defined by the local extent of the primary 
tumor (T), involvement of associated lymph nodes (N), and whether or not 
metastases (M) exist. The TNM classification for lung cancer was originally 
proposed by Mountain in the early 1970s based on an analysis of 2,155 surgically 
resected patients at the MD Anderson Cancer Center (MDACC) (7) . The 
International Association for the Study of Lung Cancer (IASLC) convened a lung 
cancer staging workgroup in 1998 and collected data on a total of 100,869 patients 
from multiple institutions worldwide (8) . The last updated staging system is the 7th 
edition of the American Joint Commission on Cancer (AJCC) and the International 
Union Against Cancer (UICC) Staging Manual. (Tables 1 and 2). 
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Table 1. TNM Classification of NSCLC 
Primary tumor (T) 
TX Primary tumor cannot be assessed, or the tumor is proven by the presence of 
malignant cells in sputum or bronchial washing but is not visualized by imaging or 
bronchoscopy  
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
T1 Tumor ≤ 3 cm in greatest dimension, surrounded by lung or visceral pleura, no 
bronchoscopic evidence of invasion more proximal than the lobar bronchus (not in 
the main bronchus); superficial spreading of tumor in the central airways (confined to 
the bronchial wall )  
T1a Tumor ≤ 2 cm in the greatest dimension 
T1b Tumor > 2 cm but ≤ 3 cm in the greatest dimension 
T2 Tumor > 3 cm but ≤ 7 cm or tumor with any of the following:  
• Invades visceral pleura 
• Involves the main bronchus ≥ 2 cm distal to the carina 
• Associated with atelectasis/obstructive pneumonitis extending to hilar region 
but not involving the entire lung 
T2a Tumor > 3 cm but ≤ 5 cm in the greatest dimension 
T2b Tumor > 5 cm but ≤ 7 cm in the greatest dimension 
T3 Tumor > 7 cm or one that directly invades any of the following:  
• Chest wall (including superior sulcus tumors), diaphragm, phrenic nerve, 
mediastinal pleura, or parietal pericardium; 
Or tumor in the main bronchus < 2 cm distal to the carina but without involvement of 
the carina 
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Or associated atelectasis/obstructive pneumonitis of the entire lung or separate tumor 
nodule(s) in the same lobe 
T4 Tumor of any size that invades any of the following: mediastinum, heart, great 
vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; or 
separate tumor nodule(s) in a different ipsilateral lobe  
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional node metastasis 
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension  
N2 Metastasis in the ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 Metastasis in the contralateral mediastinal, contralateral hilar, ipsilateral or 
contralateral scalene, or supraclavicular lymph nodes  
Distant metastasis (M) 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or 
malignant pleural (or pericardial) effusion 
M1b Distant metastasis 
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Table 2. Stages classification  
Stage T N M 
Ia T1a N0 M0 
T1b N0 M0 
Ib T2a N0 M0 
IIa T1a N1 M0 
T1b N1 M0 
T2a N1 M0 
T2b N0 M0 
IIb T2b N1 M0 
T3 N0 M0 
IIIa T1 N2 M0 
T2 N2 M0 
T3 N2 M0 
T3 N1 M0 
T4 N0 M0 
T4 N1 M0 
IIIb T4 N2 M0 
T1 N3 M0 
T2 N3 M0 
T3 N3 M0 
T4 N3 M0 
IV T Any N Any M1a or 1 
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1.1.4 Cellular classification of NSCLC 
Malignant non-small cell epithelial tumors of the lung are classified by the World 
Health Organization (WHO)/International Association for the Study of Lung 
Cancer (IASLC). There are three main subtypes of non-small cell lung cancer 
(NSCLC), including the following: 
• Squamous cell carcinoma (25% of lung cancers). 
• Adenocarcinoma (40% of lung cancers). 
• Large cell carcinoma (10% of lung cancers). 
There are numerous additional subtypes of decreasing frequency. 
WHO/IASLC Histologic Classification of NSCLC  
1. Squamous cell carcinoma.  
1. Papillary. 
2. Clear cell. 
3. Small cell. 
4. Basaloid. 
2. Adenocarcinoma.  
1. Acinar. 
2. Papillary. 
3. Bronchioloalveolar carcinoma.  
1. Nonmucinous. 
2. Mucinous. 
3. Mixed mucinous and nonmucinous or indeterminate cell type. 
4. Solid adenocarcinoma with mucin. 
5. Adenocarcinoma with mixed subtypes. 
6. Variants.  
1. Well-differentiated fetal adenocarcinoma. 
2. Mucinous (colloid) adenocarcinoma. 
3. Mucinous cystadenocarcinoma. 
4. Signet ring adenocarcinoma. 
5. Clear cell adenocarcinoma. 
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3. Large cell carcinoma.  
1. Variants.  
1. Large cell neuroendocrine carcinoma (LCNEC). 
2. Combined LCNEC. 
3. Basaloid carcinoma. 
4. Lymphoepithelioma-like carcinoma. 
5. Clear cell carcinoma. 
6. Large cell carcinoma with rhabdoid phenotype. 
4. Adenosquamous carcinoma.  
5. Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements.  
1. Carcinomas with spindle and/or giant cells. 
2. Spindle cell carcinoma. 
3. Giant cell carcinoma. 
4. Carcinosarcoma. 
5. Pulmonary blastoma. 
6. Carcinoid tumor.  
1. Typical carcinoid. 
2. Atypical carcinoid. 
7. Carcinomas of salivary gland type.  
1. Mucoepidermoid carcinoma. 
2. Adenoid cystic carcinoma. 
3. Others. 
8. Unclassified carcinoma.  
Squamous cell carcinoma  
Most squamous cell carcinomas of the lung are located centrally, in the larger 
bronchi of the lung. Squamous cell carcinomas are linked more strongly with 
smoking than other forms of NSCLC. The incidence of squamous cell carcinoma of 
the lung has been decreasing in recent years. 
Adenocarcinoma  
Adenocarcinoma is now the most common histologic subtype in many countries, 
and subclassification of adenocarcinoma is important. One of the biggest problems 
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with lung adenocarcinomas is the frequent histologic heterogeneity. In fact, 
mixtures of adenocarcinoma histologic subtypes are more common than tumors 
consisting purely of a single pattern of acinar, papillary, bronchioloalveolar, and 
solid adenocarcinoma with mucin formation. 
Criteria for the diagnosis of bronchioloalveolar carcinoma have varied widely in the 
past. The current WHO/IASLC definition is much more restrictive than that 
previously used by many pathologists because it is limited to only noninvasive 
tumors. 
If stromal, vascular, or pleural invasion are identified in an adenocarcinoma that has 
an extensive bronchioloalveolar carcinoma component, the classification would be 
an adenocarcinoma of mixed subtype with predominant bronchioloalveolar pattern 
and a focal acinar, solid, or papillary pattern, depending on which pattern is seen in 
the invasive component. However, the future of bronchioloalveolar carcinoma as a 
distinct clinical entity is unclear; a multidisciplinary expert panel representing the 
IASLC, the American Thoracic Society, and the European Respiratory Society 
proposed a major revision of the classification of adenocarcinomas in 2011 that 
entails a reclassification of what was called bronchioloalveolar carcinoma into 
newly defined histologic subgroups. 
The following variants of adenocarcinoma are recognized in the WHO/IASLC 
classification: 
• Well-differentiated fetal adenocarcinoma. 
• Mucinous (colloid) adenocarcinoma. 
• Mucinous cystadenocarcinoma. 
• Signet ring adenocarcinoma. 
• Clear cell adenocarcinoma. 
Large cell carcinoma  
In addition to the general category of large cell carcinoma, several uncommon 
variants are recognized in the WHO/IASLC classification, including the following: 
• LCNEC. 
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• Basaloid carcinoma. 
• Lymphoepithelioma-like carcinoma. 
• Clear cell carcinoma. 
• Large cell carcinoma with rhabdoid phenotype. 
Basaloid carcinoma is also recognized as a variant of squamous cell carcinoma, and 
rarely, adenocarcinomas may have a basaloid pattern; however, in tumors without 
either of these features, they are regarded as a variant of large cell carcinoma. 
Neuroendocrine tumors  
LCNEC is recognized as a histologically high-grade non-small cell carcinoma. It 
has a very poor prognosis similar to that of small cell lung cancer (SCLC). Atypical 
carcinoid is recognized as an intermediate-grade neuroendocrine tumor with a 
prognosis that falls between typical carcinoid and high-grade SCLC and LCNEC. 
Neuroendocrine differentiation can be demonstrated by immunohistochemistry or 
electron microscopy in 10% to 20% of common NSCLCs that do not have any 
neuroendocrine morphology. These tumors are not formally recognized within the 
WHO/IASLC classification scheme because the clinical and therapeutic 
significance of neuroendocrine differentiation in NSCLC is not firmly established. 
These tumors are referred to collectively as NSCLC with neuroendocrine 
differentiation. 
Carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements  
This is a group of rare tumors. Spindle cell carcinomas and giant cell carcinomas 
comprise only 0.4% of all lung malignancies, and carcinosarcomas comprise only 
0.1% of all lung malignancies. In addition, this group of tumors reflects a 
continuum in histologic heterogeneity as well as epithelial and mesenchymal 
differentiation. On the basis of clinical and molecular data, biphasic pulmonary 
blastoma is regarded as part of the spectrum of carcinomas with pleomorphic, 
sarcomatoid, or sarcomatous elements. (9) 
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1.1.5 Biomolecular characterization and target therapy 
In recent years, attention has been paid to the role that ‘driver mutations,’ such as 
epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), 
have in the tumorigenesis of adenocarcinomas, and their potential use as targets for 
therapy (10-12). Recent data suggest EGFR may also serve as a prognostic factor, 
in addition to its role as a predictive factor, as patients-bearing EGFR mutations 
have shown favorable clinical outcomes even with conventional chemotherapy 
(13). EGFR mutations, which are associated with objective responses to single-
agent TKI therapy in lung adenocarcinomas, are preferentially observed in a 
specific subset of patients: females of East Asian ethnicity who have never smoked 
and who have adenocarcinoma with lepidic growth pattern (formerly 
bronchioloalveolar carcinoma) (13). In adenocarcinomas, the majority of mutations 
have been identified in exons 18–21 of the EGFR gene. These mutations can be 
roughly classified into three major categories: in-frame deletions in exon 19, 
insertion mutations in exon 20, and missense mutations in exons 18–21. 
Different EGFR mutations have different signaling properties, but most mutations 
affect the ATP binding cleft, where targeting TKIs compete for binding. The most 
frequent mutations were located at exon 19 and exon 21. There are over 20 variant 
types of exon 19 deletions, with the most common including delE746-A750, 
delL747- T751insS, and delL747-P753insS. L858R, in exon 21, is the second most 
frequent mutation. Additional mutations are located at exon 18 including G719C, 
G719S, G719A, and S720F and mutations found in exon 21 including L861Q and 
L861R. 
The exon 20 insertions frequently associated with EGFR-TKI non-responsiveness, 
including D770- N771insNPG, D770-N771insSVQ, D770-N771insG, and point 
mutations, including T790M, V769L, and N771T. The most important mutation in 
exon 20 is T790M, which is associated with a small fraction of adenocarcinomas 
with primary resistance to EGFR TKI and over one-half of the patients with 
acquired resistance to EGFR TKI. The ability to detect multiple driver mutations in 
lung adenocarcinoma has revolutionized the medical management of this disease 
and multiplexed testing for all common driver mutations will provide physicians 
with a more precise guide for therapy (14). Other driver mutations have been 
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identified in NSCLC (in about 60% of cases) and in Figure 1 are represented the 
frequency of the founded alterations (15). 
It is noteworthy that 95% of molecular lesions were mutually exclusive. 
 
 
 
Figure 1. Frequency of major driver mutations in signaling molecules in lung 
adenocarcinomas (16). 
 
 
The ALK gene encodes a receptor tyrosine kinase found in a number of fusion 
proteins consisting of the intracellular kinase domain of ALK and the amino 
terminal portions of different genes. The EML4–ALK fusion is a rare abnormality 
detected in 3–13% of patients with adenocarcinomas (17). It has been reported that 
although ALK-fusion positive lung cancers are resistant to the EGFR TKIs, 
gefitinib, and erlotinib, they are sensitive to small molecule TKIs against ALK. 
ALK TKIs (ALK TKI), including crizotinib, are effective treatments in preclinical 
models for patients with ALK-fusion cancers (18).   
 
Based on the molecular feature of patients with adenocarcinoma of the lung, an 
algorithm that defines the rationale in selecting patients who could benefit from 
EGFR and EML4–ALK targeted therapy have been suggested (Figure 2). 
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Figure 2. Suggested algorithm for molecular testing for patients with lung 
adenocarcinoma. The algorithm defines the rationale in selecting patients who could 
benefit from EGFR and EML4–ALKA targeted therapy. Adenocarcinoma cases are 
subjected to testing for EGFR mutations. The EGFR mutation-positive cases (15%) are 
further divided into responsive and resistant groups according to their mutation profiles. A 
responsive mutation predicts a response rate of 91% and a resistant mutation predicts a 
response rate of 9%. The presence of wild-type EGFR characterizes about 85% of the 
adenocarcinomas, and predicts the likelihood of non-responsive to EGFR TKI. Tumors 
with wild-type EGFR are further tested for EML4–ALK rearrangement. Although EML4–
ALK rearrangement is found in only 3% of patients with lung adenocarcinoma, its presence 
predicts a 53% probability of response to targeted therapy (16). 
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Another common alteration of NSCLC is the KRAS mutation. Mutations in KRAS 
are one mechanism of primary resistance to gefitinib and erlotinib. KRAS 
mutations are almost exclusively detected in codons 12 and 13 of exon 2, resulting 
in EGFR independent intracellular signal transduction activation. The KRAS 
mutations were found in 17% (21/121) of African–American patients compared 
with 26% (125/476) of Caucasian patients (19). KRAS mutations in 
adenocarcinoma are usually associated with wild-type EGFR and non-
responsiveness to EGFR TKI therapy. Considering the mutually exclusive presence 
of EGFR, EML4-ALK and KRAS mutations, an alternative alghoritm of analysis 
have been proposed (Figure 3). 
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Figure 3. Alternative algorithm for molecular testing for patients with lung 
adenocarcinomas. Approximately 25% of lung adenocarcinomas harbor KRAS 
mutations, which predict non-response to EGFR TKI therapy. Of the remaining KRAS-
negative lung adenocarcinomas, B20% harbor EGFR mutations, which are associated with 
responsiveness to EGFR TKI therapy. EGFR mutation negative cases may benefit from 
additional testing for the EML4–ALK rearrangement, which will be helpful in selecting 
patients potentially eligible for ALK targeted therapy (16). 
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1.1.6 Conventional chemotherapy 
Despite remarkable advances in the targeted treatment of non-small cell lung cancer 
(NSCLC) over the past several years, chemotherapy remains of paramount 
importance in the treatment of advanced NSCLC. Even in patients whose tumors 
contain EGFR activating mutations or ALK gene rearrangements and are treated 
with first line tyrosine kinase inhibitors, resistance invariably develops, with 
chemotherapy remaining the cornerstone of subsequent therapy. In profiling 
mutations of 1,000 metastatic lung adenocarcinoma patients, although the Lung 
Cancer Mutation Consortium was able to identify actionable mutations, including 
molecular aberrations linked to approved drugs and clinical trials in 54% of cases 
(1), in only a small minority, about 14-18% in Western populations, are there 
approved targeted drugs (EGFR and ALK TKIs) with which to treat them. As of 
yet, no drugs targeting oncogenic-driver pathways have been approved in squamous 
cell lung cancers, though clinical trials are ongoing. With the majority of advanced 
lung cancer patients not harboring actionable driver mutations with paired targeted 
agents that effectively improve outcomes, advancing chemotherapy regimens 
through rational drug combinations and discovery of new potent chemotherapeutics 
remains critical.  
Although recently implemented treatment guidelines recommend that patients with 
advanced stage NSCLC whose tumors harbor EGFR activating mutations or ALK 
gene rearrangements be treated first line with erlotinib or crizotinib, respectively, it 
is with the realization that there is no overall survival benefit to patients with EGFR 
mutated cancers whether they receive an EGFR TKI first line or second line. This 
TKI first recommendation is true even in patients with tumor-related poor 
performance status.  
Cytotoxic agents active against NSCLC are platinum analogues (cisplatin-
carboplatin), ifosfamide, mytomycin C, vindesine, vinblastine, etoposide, 
gemcitabine, paclitaxel, docetaxel, vinorelbine, pemetrexed. For ‘fit’ patients who 
do not have an oncogene-driven cancer, platinum doublet chemotherapy (with 
consideration of bevacizumab in non-squamous histology patients) remains the 
cornerstone of treatment. In an attempt to preserve efficacy and minimize toxicity, 
platinum free combinations of newer agents have been tested against conventional 
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platinum-based combinations. Although a recent meta-analysis of 16 randomized 
trials found that the efficacy was comparable between non-platinum doublets of 
third-generation agents and platinum-based doublets for pooled overall survival 
(HR =1.03, 95% CI: 0.98-1.08, P=0.290), all evidence based guidelines support 
platinum-based therapy as standard of care (20). 
Utilizing DNA repair enzymes as biomarkers for better selecting front-line 
chemotherapy is an area of active investigation. Low ERCC1 expression by either 
IHC or RT-PCR has been shown in preliminary studies to be a potential biomarker 
of benefit to platinum compounds and low RRM1 a potential biomarker of benefit 
to gemcitabine. The ERCC1 enzyme removes platinum-induced DNA adducts, and 
thus low ERCC1 levels are associated with platinum sensitivity (21). RRM1 is a 
subunit of ribonucleotide reductase which is the main target of gemcitabine; thus, 
low RRM1 levels are associated with gemcitabine sensitivity (22). 
Pemetrexed is a multi-targeted anti-folate employed: with platinum derivates for 
first-line treatment, as single agent for subsequent lines of treatment, and as 
maintenance therapy. 
In the landmark JMDB trial, Scagliotti et al. demonstrated no difference in overall 
survival between cisplatin/gemcitabine and cisplatin/pemetrexed as first-line 
treatment of patients with metastatic NSCLC. However, in a preplanned subset 
analysis the cisplatin-pemetrexed combination was superior in non-squamous 
histology with a median overall survival of 12.6 months in the cisplatin-pemetrexed 
arm and 10.9 months in the cisplatin-gemcitabine arm (HR =0.84; 95% CI: 0.71-
0.99; P=0.03) (23). By contrast, patients with squamous carcinoma had a worse 
median overall survival in the cisplatin-pemetrexed arm than in the cisplatin-
gemcitabine arm (9.4 vs. 10.8 months; HR =1.23; 95% CI: 1.0-1.5; P=0.05). 
A consistent survival advantage with pemetrexed was observed especially in non-
squamous NSCLC (which represented the majority of the patients). A meta-
analysis of five trials (three first-line trials, one second-line trial, one maintenance 
trial) confirmed that pemetrexed, when compared with alternative treatments or 
placebo, is consistently associated with a significant overall survival improvement 
in non-squamous histology (HR =0.82) but not in squamous histology (HR =1.19) 
(24). 
In Table 3 is presented the response of 3rd generation cytotoxic drugs as 
monotherapy and in combination with platinum analogues. 
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Table 3. Results of six new agents in advanced NSCLC as monotherapy and in 
combination with platinum analogues (Pt) 
 
 
The diagnosis and management paradigm of metastatic NSCLC has transitioned 
into an algorithm of presence or absence of oncogene addiction as a key branch 
point to selecting appropriate treatment. As described above, with the identification 
of driver mutations such as EGFR and ALK, EGFR-TKIs and crizotinib are 
supplanting traditional chemotherapy for upfront treatment of these patients. 
However, initial TKI responders inevitably relapse due to acquired resistance. More 
recently, an added layer of complexity related to intrapatient tumor heterogeneity 
has been observed, particularly relevant to the clonal evolution of somatic 
mutations from the primary tumor to metastatic lesions and the mixed response to 
treatment in different tumor sites. Therefore, an area of focus has therefore been on 
interrogating the combination of novel targeted agents together with chemotherapy 
to optimize efficacy, survival and overcome acquired resistance. 
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1.2 Epigenetic and cancer 
Epigenetics is the study of heritable changes in gene activity that are not caused by 
changes in the DNA sequence; the term is also used to describe the study of stable, 
long-term alterations in the transcriptional potential of a cell, not necessarily 
heritable. Unlike simple genetics based on changes in DNA sequence, the changes 
in gene expression or cellular phenotype of epigenetics have other causes, thus use 
of the term epi- genetics.  
Examples of mechanisms that produce such changes are DNA methylation and 
histone modification, each of which alters how genes are expressed without altering 
the underlying DNA sequence. 
 
Figure 4. Epigenetic mechanisms 
(http://en.wikipedia.org/wiki/File:Epigenetic_mechanisms.jpg) 
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1.2.1 Methylation 
DNA methylation is probably the most well known epigenetic mark able to 
discriminate between normal cells and tumor cells in humans. The "normal" CpG 
methylation profile is often inverted in cells that become tumorigenic (25). In 
normal cells, CpG Islands localized at gene promoters are generally unmethylated, 
while other individual CpG dinucleotides throughout the genome tend to be 
methylated. Conversely, in cancer cells, CpG islands preceding tumor suppressor 
gene promoters are often hypermethylated, while CpG methylation of oncogene 
promoter regions is often decreased. 
Hypermethylation of gene promoters can result in silencing of those genes. This 
type of epigenetic mutation is dangerous when genes that regulate the cell cycle are 
silenced, allowing cells to grow and reproduce uncontrollably, leading to 
tumorigenesis (26). Genes commonly found to be transcriptionally silenced due to 
promoter hypermethylation include: Cyclin-dependent kinase inhibitor p16, a cell-
cycle inhibitor; p53, a tumor suppressor gene; MGMT, a DNA repair gene; APC, a 
cell cycle regulator; MLH1, a DNA-repair gene; and BRCA1, another DNA-repair 
gene (25, 26).  
Hypomethylation of CpG dinucleotides in other parts of the genome leads to 
chromosome instability due to mechanisms such as loss of imprinting and 
reactivation of transposable elements.(27) In healthy cells, CpG dinucleotides of 
lower densities are found within coding and non-coding intergenic regions. 
Parasitic repetitive sequences, centromeres and oncogenes are often repressed 
through methylation. 
The entire genome of a cancerous cell contains significantly less methylcytosine 
than the genome of a healthy cell. In fact, cancer cell genomes have 20-50% less 
methylation at individual CpG dinucleotides across the genome (27). In cancer cells 
“global hypomethylation” due to disruption in DNA methyltransferases (DNMTs) 
may promote mitotic recombination and chromosome rearrangement, ultimately 
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resulting in aneuploidy when the chromosomes fail to separate properly during 
mitosis (27). 
CpG island methylation is important in gene expression regulation, yet cytosine 
methylation can lead directly to destabilizing genetic mutations and a precancerous 
cellular state. Methylated cytosines make hydrolysis of the amine group and 
spontaneous conversion to thymine more favorable. They can cause aberrant 
recruitment of chromatin proteins. Cytosine methylations change the amount of UV 
light absorption of the nucleotide base, creating pyrimidine dimers. When mutation 
results in loss of heterozygosity at tumor suppressor gene sites, these genes may 
become inactive. Single base pair mutations during replication can also have 
detrimental effects (26). 
 
1.2.2  Histone modifications 
Eukaryotic DNA has a complex structure. It is generally wrapped around special 
proteins called histones to form a structure called a nucleosome. A nucleosome 
consists of 2 sets of 4 histones: H2A, H2B, H3, and H4. Histone H1 contributes to 
DNA packaging outside of the nucleosome. Specific histone modifying enzymes 
can add or remove functional groups to the histones, and these modifications 
influence the level of transcription of the genes wrapped around those histones and 
the level of DNA replication. Therefore, the histone modification profiles of 
healthy and cancerous cells are different. 
In comparison to healthy cells, cancerous cells exhibit decreased monoacetylated 
and trimethylated forms of histone H4 (decreased H4ac and H4me3). Interestingly, 
loss of histone H4 Lysine 16 acetylation (H4K16ac), which is a mark of aging at 
the telomeres, specifically loses its acetylation.  
Other histone marks associated with tumorigenesis include increased deacetylation 
(decreased acetylation) of histones H3 and H4, decreased trimethylation of histone 
H3 Lysine 4 (H3K4me3), and increased monomethylation of histone H3 Lysine 9 
(H3K9me) and trimethylation of histone H3 Lysine 27 (H3K27me3). These histone 
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modifications can silence tumor suppressor genes despite the drop in methylation of 
the gene’s CpG island (an event that normally activates genes) (28). 
Modification of histones by acetylation affects gene transcription by changing the 
chromatin structure that modulates the accessibility of transcription factors to their 
target DNA. As consequence, it plays an important role in regulation of gene 
expression. Additionally, acetylation and/or deacetylation of non-histonic proteins 
modify many important cell functions (29-30). 
The acetylation state of histones and other proteins is maintained by histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) enzymes. HATs catalyze 
the transfer of an acetyl group from acetyl-CoA to lysine residues in proteins, 
whereas HDAC removes it. Depending on the mechanisms of removing the acetyl 
group, HDACs can be divided into two distinct families. The “classical family” 
comprises Zn2+-dependent HDACs, the second family of HDACs depends in 
catalysis on NAD+ and subsequently, O-acetyl-ADP-ribose and nicotinamide are 
formed as a result of the acetyl transfer (31). Furthermore, based on the homology 
to their yeast analogues, HDACs are divided into four classes. Class I are located in 
the nucleus and includes HDACs 1, 2, 3 and 8. HDACs 4, 5, 7 and 9 are members 
of class IIa, while isoforms 6 and 10 that are located both in the cytoplasm and 
nucleus are classified as class IIb. Class IV, which exhibits features of class I and 
II, includes only HDAC11. NAD+-dependent homologues 1-7 of the yeast Sir2 
proteins (sirtuins) are designed as class III of HDACs, and have mono-ADP-
ribosyltransferase activity. HATs, “functional opponents” of HDACs, are divided 
into Gcn5/PCAF N-acetyltransferases (GNATs) and MYST HATs. Although these 
two groups of HATs are the major enzymes catalyzing N-acetyltransferase activity, 
other proteins also exhibit this acetylase activity (32). 
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1.3 Histone deacetylase inhibitors 
During the last few decades, several approaches have been used in an effort to 
discover new more effective anticancer drugs. Many promising compounds have 
been investigated. However, chemoresistance that may arise during chemotherapy 
is one of the main causes of failure of treatment. Epigenetic changes are emerging 
as part cause of the chemoresistence. Of these, histone acetylation and 
deacetylation have been investigated as therapeutic targets because of their 
importance in regulation of gene expression. Changes in histone acetylation 
influence chromatin condensation and these alterations influence gene 
transcription. The balance between histone transacetylases and deacetylases is often 
damaged in cancer, leading to changed expressions of tumor suppressor genes 
and/or proto-oncogenes (33, 34). 
 
 
1.3.1 Histone deacetylases and cancer 
 
HDACs class I and II levels vary in different cancer cells. HDAC1 is overexpressed 
in prostate and gastric cancers, where it signalizes poor prognosis, as well as in 
lung, esophageal, colon and breast cancers (35-37). High levels of HDAC2 have 
been found in colorectal, cervical and gastric cancers (38, 39). In addition, HDAC3 
is overexpressed in gastric, prostate and colorectal cancer (40), and high expression 
of HDAC1 and 2 correlates with reduced patient survival in colorectal carcinomas. 
HDAC6 is highly expressed in breast cancer, HDAC8 is over-expressed in 
neuroblastoma cells and its overexpression correlates with metastasis and advanced 
stage of disease with poor prognosis. Expression of HDAC11 is increased in 
rhabdomyosarcoma (41). 
Class III HDACs play an important role in carcinogenesis. Some act as 
antioncogenes while others influence tumors by controlling the cell metabolism 
(42). Decreased activities of HDACs are associated with suppressed tumor cell 
development and growth (43,44). Moreover mutations of HDAC4 have been 
identified in breast cancer samples (45) and mutation of HDAC2 that cause protein 
truncation was found in human epithelial cancer cell lines. 
 
25 
 
 
 
 
Figure 5. HDAC structure and localization (46) 
 
 
 
 
1.3.2 Type of Histone deacetylase inhibitors 
 
The results from various studies indicate that HDAC inhibitors increase the anticancer 
efficacy of additional therapy modalities and they therefore would be very efficient 
in the clinic together with other anticancer treatment modalities including ionizing 
radiation and/or chemotherapy. For this reason, investigation of the clinical 
application of HDAC inhibitors has increased with over 490 clinical trials for cancer and a 
few for other diseases (47). HDAC inhibitors have also be found to be effective for 
treatment of other diseases. Some HDAC inhibitors have antimalarial properties and are 
studied as new possible drugs for the treatment of malaria. There is also some evidence 
that HDAC pan-inhibitors and HDAC III inhibitors possess anti-inflammatory effects in 
models of asthma (48). They can be classified according to their chemical structure into 
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four groups: 1) hydroxamic acids; 2) aliphatic acids; 2) benzamides; 4) cyclic 
tetrapeptides. 
1) Hydroxamic acids trichostatin A (TSA), vorinostat (suberoylanilide hydroxamic acid, 
SAHA) which was approved by the FDA as the first HDAC inhibitor for the treatment of 
relapsed and refractory cutaneous T-cell lymphoma (CTCL) (49), belinostat (PXD-101) 
and panobinostat (LBH589) are pan-HDAC inhibitors. 
2) The aliphatic acids [valproic acid (VPA), butyric acid and phenylbutyric acid] are weak 
inhibitors of HDAC I and IIa (50). 
3) Benzamides that include entinostat (SNDX-275, MS-275) and mocetinostat 
(MGCD0103) are isoform selective inhibitors of HDAC I and mocetinostat inhibits also IV 
HDAC (51). 
4) The cyclic tetrapeptides, inhibitors of class I HDACs (romidepsin inhibits also HDAC 4 
and 6), are cyclic hydroxamic acids containing peptides: romidepsin (depsipeptide, FK228, 
FR901228), apicidin and trapoxinand. Of these, romidepsin that was approved by the FDA 
and the EuMedicines Agency to treat CTCL and peripheral T cell lymphomas, is most 
effective (52). It is a prodrug which is activated to a metabolite that chelates the zinc 
ions in the active center of the HDAC of class I.
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1.3.3 HDACi as anticancer drugs 
The clinical development of HDACi is an active area of study. There are currently at least 
15 different HDACi in clinical trials both as monotherapy and in combination for both 
hematological malignancies and for solid tumors. 
Vorinostat HDACi is the most advanced in clinical use. In fact it is the first that have been 
approved by the FDA for the treatment of cutaneous T-cell lymphoma (53, 54). 
LBH-589, which is in phase I and II clinical trials, appears to have greater efficacy of 
Vorinostat. Preliminary evidences indicate a capacity to induce disease stabilization, partial 
response, and, in few cases, a transient complete response. 
Clinical trials with several HDACi are performed on patients with a wide variety of 
hematological and solid tumors including chronic lymphoid leukemia, acute myeloid 
leukemia, multiple myeloma, cancer of the head and neck, melanoma, and cancers of 
various organs such as brain, lung , breast, ovary, kidney and pancreas. The evidence 
accumulated to date show that the HDACi may be more useful in combination with other 
cytotoxic drugs and / or targeted. 
Since many chemotherapeutic agents exert their antitumor activity damaging directly or 
indirectly the DNA, the combined treatment with HDACi can sensitize cancer cells with a 
combination of DNA damage and altered chromatin remodeling (55).  
In fact it is known that the HDACi synergize with γ radiation, increasing the cytotoxic 
effect in various types of tumors. The mechanisms by which the HDACi sensitize cancer 
cells to DNA damage are different. 
The loss of chromatin compaction as a result of the core histone hyperacetilation can 
increase the accessibility of genotoxic agents and increase efficiency. So in this model the 
HDACi potentiate the effect induced by genotoxic agents. 
This may be due to the effect induced by the production of ROS, acting genotoxic, 
following treatment with HDACi. In addition there is also evidence that HDACi can 
suppress the mechanisms of DNA repair. 
In fact, the modulation of the phosphorylation of histone H2AX in the site where it is 
damaged the DNA is important to allow repair. The phosphorylated form of H2AX can be 
induced by treatment with HDACi and the sites of H2AX phosphorylated by DNA damage 
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persist after exposure to HDACi, this results in a decreased ability to repair DNA strand 
break  (56). Many of the components of the path of DNA repair such as ATM, NBS1, 
PARP1, Ku 70 and 80 are adjusted by acetylation. 
Finally, the HDACi can sensitize cells to apoptosis induced by cytotoxic substances by 
decreasing the activation threshold for apoptosis by regulating the expression of pro-and 
antiapoptotic proteins (57). 
As already said, HDACi may act on mechanisms that regulate protein degradation via the 
proteasome involvement, in which also operates the Hsp90 chaperone. For this reason, 
studies have been conducted to evaluate the efficacy of cotreatment with HDACi and 
Hsp90 inhibitors such as 17-AAG. 
The synergistic effect of these two treatments leads to a more efficient degradation of 
oncoproteins whose half-life is regulated by this chaperone such as BCR-ABL, resulting in 
a greater mortality of tumor cells. 
Another cotreatment with promising results is that with HDACi together with proteasome 
inhibitors, such as bortezomib. 
The inhibition of proteasomal activity leads to an accumulation of ubiquitilated proteins.  
This causes the endoplasmic reticulum stress and apoptosis. Cancer cells try to survive this 
stress "bundling" ubiquitilated proteins into a structure called cytoprotective perinuclear 
aggresome. 
HDAC6 binds ubiquitilated proteins bringing to aggresome. So the inhibition of HDAC 
does not allow the formation of aggresome leading to the dispersion of microaggregates 
toxic in the cell. This proteotoxicity promotes the activation of the ER stress and induction 
of apoptosis (58). 
The main side effects associated to HDACi include fatigue, nausea, dehydration, diarrhea, 
and thrombocytopenia. In general, these effects are transient and cease with the end of 
treatment. 
The development of clinical approaches with HDACi are still a matter of study with 
different substances. The HDACi constitute a group of promising anti-tumor substances, 
since they can induce death of malignant cells of a broad category of solid tumors and not. 
The mechanism by which it performs this action is yet to fully understand. But it is clear 
that these chemicals can cause growth arrest and death of cancer cells by different 
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mechanisms such as apoptosis, or autophagy, inhibition of metastasis and angiogenesis and 
impaired immune response. Normal cells are relatively resistant to cell death induced by 
HDACi. The basis of this resistance are not known. It has been speculated that the multiple 
defects of cancer cells do not allow to counteract stress induced by HDACi which fail, 
however, to carry out normal cells. In fact, the HDACi are well tolerated in clinical trials. 
While HDACi have shown good efficacy as anticancer agents in preclinical studies, in 
clinical approaches on a wide variety of tumors, only a portion of patients with certain 
diagnoses have responded to treatment with HDACi. 
 From this it is clear that is still important to study the mechanisms of action and the 
markers that can predict the effectiveness of response (59) 
 
 
Figure 6. HDACi as anticancer drugs 
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 1.3.4 Valproic Acid 
Valproic acid (VPA) has been synthesized for the first time in 1882 but only in 
1963 his efficacy as antiepileptic was discovered. Since then, the VPA has been 
used as a drug for the treatment of epilepsy, and also for other neurological 
disorders. Only in recent years its function as an inhibitor of histone deacetylase has 
been discovered (Figure 7) (60). Valproic acid is a small branched fatty acid with 8 
carbon atoms, its molecular structure offers many possibilities for chemical 
modifications (Figure 7). 
Figure 7. Chemical Structure of Valproic Acid (60) 
 
The analogues of VPA, including its metabolites, show overlapping but distinct 
activities that affect seizures, neuronal processes, cell proliferation and 
differentiation. Studies carried out in recent years have confirmed that VPA and its 
analogues show antitumor action. Following the discovery of this antiproliferative 
activity of VPA in cancer cells, several studies have shown that this event is 
associated with the differentiation of neoplastic cells and is correlated with the 
inhibition of histone deacetylases. 
Since it is already used as a drug, some effects on humans are already known. 
Unlike other short chain fatty acids such as butyric acid in the serum half-life of 
this drug is somewhat prolonged, between 7-16 h. 
Valproic acid is generally well tolerated, at therapeutic concentration in plasma 
between 50 and 100 micrograms / ml, from patients treated for neurological 
problems. The major side effects are detectable in the liver, is also known to have 
teratogenic effect. 
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As deacetylase inhibitor, it has been observed that Valproic acid induces the 
hyperacetilation of the amino-terminal tails of histones H3 and H4 in vitro and in 
vivo and has been demonstrated its ability to inhibit histone deacetylase from the 
standpoint of enzyme (60). It was subsequently shown that valproic acid and 
similar compounds, inhibit histone deacetylase class I through two different 
mechanisms: inhibiting the catalytic activity and inducing the proteosomal 
degradation (61). 
The VPA unlike the TSA, does not inhibit the activity of HDAC-6 and 10. The 
anti-proliferative effect of valproic acid was shown initially by Regan in 1985, who 
observed a decrease in mitotic index in murine neuroblastoma and glioma. This 
effect was reversible and not caused by cytotoxicity (62) 
Valproic acid shows a potent antitumor effect in a wide range of models both in 
vivo and in vitro, by modulating several mechanisms including cell cycle arrest, 
apoptosis, angiogenesis, metastasis, differentiation and senescence . These effects 
appear to be cell type specific and may depend on the level of differentiation and 
genetic alterations. 
The majority of preclinical studies as anticancer drug have been addressed so far in 
hematologic malignancies, but there are also many studies on solid tumors used as a 
template. It has been observed that valproic acid induces apoptosis in many human 
leukemic lines (branch B, T and myeloid) by triggering the release of cytochrome c 
from mitochondria and activation of caspase-3, -8 and -9. 
When the cell line MV4-11 was pre-treated with an inhibitor of caspases, the pro-
apoptotic effect of valproic acid was inhibited in the nucleus, but not on the cell 
surface (63). These results allow to assume that valproic acid can activate two 
different apoptotic signaling pathways: a caspase-dependent and the other caspase-
independent. The antiproliferative effect of VPA was also examined HCC cell lines 
and primary human hepatocytes. 
In spite of the fact that the hepatocellular carcinomas are generally very resistant to 
chemotherapy, VPA inhibits proliferation in cancer cell lines but not in primary 
hepatocytes (64). The inhibition of proliferation was associated with increased 
expression of p21 in tumor cells of glioma, thyroid, melanoma, ovarian cancer, and 
medullo blastoma. The pro-apoptotic effect was observed in many models and 
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associated with different components of the apoptotic pathways. In particular, an 
increase of pro-apoptotic factors such as Bik, in breast cancer cell lines, and Bax in 
thyroid cells, were detected. Moreover a decrease of anti-apoptotic proteins such as 
Bcl-2 and Bcl-xL in prostate cancer cells and thyroid were also observed. These 
studies have been addressed using concentrations ranging from 0.2 mM to 10 mM. 
Unfortunately, however, the doses of valproic acid necessary to obtain an in vivo 
antitumor effect are very high, thus causing the significant side effects and limiting 
its use in clinical practice. Studies have shown that the weak activity of the drug 
could be attributed to its inability to access the zinc cation in the pocket of HDAC 
enzyme activity. Coupling valproic acid with molecules capable of enhancing this 
activity could boost its pharmacological effects. In particular, the addition of a 
tiosulphonate group, linked via an ester or an amide group, would lead to the 
liberation of a-SH group, required for the de acetylation of lysine residues 
acetylated (65).  
The hydrogen sulfide (H2S) is produced endogenously in a constant and is involved 
in many processes such as neuro-modulation, hypertension, inflammation, 
hemorrhagic shock and edema. It plays some protective roles against oxidative 
stress and in the maintenance of vascular tone (66). 
 
1.3.5 Combination of Histone Deacetylase Inhibitors with Other Therapeutic 
Regimens 
The results from in vitro and in vivo experiments using various cancer cells have 
demonstrated that combination of HDAC inhibitors with a variety of anticancer 
drugs have synergistic or additive effects (67). Chemotherapeutic combinations 
with HDAC inhibitors have also been used in clinical trials (68). Several types of 
therapies have been investigated in combination with HDAC inhibitors. 
1) HDAC inhibitors were combined with other epigenetic modifiers. Inhibitors of 
DNA methyl transferases 5-azacytidine (azacitidine) and 5-aza-2’-deoxycytidine 
(decitabine) had increased antitumor effects when used with HDAC inhibitors (69, 
70). 
2) Promising results have been reported for combinations of HDAC inhibitors and 
ROS-generating agents. One such agent, adaphostin, increases entinostat and 
33 
 
vorinostat induced apoptosis in leukemia cells (71). In addition depletion of GSH, 
that is a ROS scavenger, increases the effects of vorinostat on AML cells (72). 
3) Other drugs that have been combined with HDAC inhibitors are microtubule 
stabilizers. VPA increases the toxic effects of paclitaxel in anaplastic thyroid 
carcinoma cells due to their interaction with the tubulin β subunit. VPA enhances 
tubulin hyperacetylation that stabilizes microtubule structures (73). Similar 
enhancement of apoptosis was observed in endometrial carcinoma cells treated with 
trichostatin A and paclitaxel caused by the activation of the intrinsic mitochondria-
dependent pathway. Trichostatin A also stabilizes microtubules via α-tubulin 
acetylation both in vitro and in vivo (74). 
4) Another effective combination of HDAC inhibitors is that with proteasome 
inhibitors. Cancer cell death due to a combination of proteasome and HDAC 
inhibitors is caused by induction of oxidative stress, endoplasmic reticulum (ER) 
stress and stimulations of JNK. Bortezomib, marizomib (NPI-0052) and 
carfilzomib are proteasome inhibitors which have been combined with HDAC 
inhibitors. Treatment of multiple myeloma cells with bortezomib 
made the cells more sensitive to vorinostat and sodium butyrate induced apoptosis 
(75). Mechanisms of the anticancer effects of a combination of proteasome and 
HDAC inhibitors are mitochondrial damage, disruption of aggresome formation, 
stimulations of JNK and caspases and enhancement of oxidative and ER stress (75, 
76). 
5) Numerous studies show synergisms or additive effects combining the HDAC 
inhibitors and DNA damaging agents such as topoisomerase inhibitors, DNA 
intercalators, inhibitors of DNA synthesis and agents covalently modifying DNA 
(i.e. doxorubicin, epirubicin, etoposid, cisplatin, 5-fluorouracil, melphalan, and 
temozolomide and ionizing radiation in many cancer cell lines) (77). 
 
1.3.6 Clinical Studies and Registered Drugs 
Several HDAC inhibitors of different structural classes are under clinical 
development (see Table 4). These include the short-chain fatty acids (phenyl 
butyrate and valproic acid); the hydroxamic acids [vorinostat (ZolinzaR, SAHA); 
panobinostat (LBH589); PCI-24781 and belinostat (PXD101)]; the cyclic 
tetrapeptides [romidepsin (IstodaxR, FK228); and the benzamides entinostat (MS-
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275)]. Two HDAC inhibitors, vorinostat and romidespin, have been approved by 
the US FDA for treating patients with progressive, persistent or recurrent cutaneous 
T-cell lymphoma (CTCL) after one or more lines of chemotherapy and romidepsin 
for patients suffering from peripheral T cell lymphoma who received at least one 
prior Therapy (78, 79). Vorinostat had modest activity as a single agent. Its 
response rate is 10-20% in AML and MDS patients. However this HDAC inhibitor, 
in combination with 5-azacitidine, increased response rate by 30%. The 
combination of vorinostat with idarubicin and cytarabine had synergistic activity 
that was maximal when vorinostat preceded cytarabine. In a phase II trial, the 
response rate of 85% of the combination was superior to that of idarubicin and 
cytarabine alone; notably, there were responses in all patients with FLT3-ITD 
mutations (80, 81) 
Table 4. HDAC inhibitors under clinical development  
 
HDAC inhibitors also appear to be active in AML, lymphomas and myelodysplastic 
syndromes (MDS). Inhibition of HDACs mediates the epigenetic gene silencing in 
common translocations associated with certain hematological malignancies such as 
AML/ETO fusion protein (82). MGCD0103 (Mocetinostat) was evaluated in a 
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clinical phase II trial for the treatment of patients with refractory chronic 
lymphocytic leukemia (CLL). This HDAC inhibitor alone showed only limited 
efficacy. For this reason, mocetinostat in combination with other agents such as 
conventional chemotherapeutic drugs was recommended (83). LBH-589 
(Panobinostat) underwent phase I and II clinical studies for the treatment of solid 
and hematologic maligancies and phase III clinical trials against CTCL and CML. 
Two phases I clinical trials showed promising results using LBH-589 in an oral and 
intravenous form against CTCL (84) and leukemias, respectively (85). Both studies 
found increased acetylation of histones in tumor cells that was associated with 
apoptosis. LBH-589 also underwent several phase III clinical trials against CTCL 
too and leukemia in its oral form and showed positive effect for the treatment of 
those diseases. Despite promising results in the treatment of CTCL, vorinostat and 
romidepsin have not been effective in studies that involved solid tumors. Clinical 
trials have assessed their efficacy against different solid tumors, e.g. 
neuroendocrine tumors, glioblastoma multiforme, mesothelioma, refractory breast, 
colorectal, NSCL, prostate, head and neck, renal cell, ovarian, cervical and thyroid 
cancers. None of the patients included in these trials showed at least partial 
response to treatment and they suffered from side effects (86). Study that assessed 
whether VPA modulates the efficacy of radiochemotherapy with temozolomide in 
glioblastoma patients showed that combined therapy with VPA was more effective 
over patients treated without HDAC inhibitors. The authors of this study reasoned 
that the improvement in the arm with VPA was due to the inhibition of HDAC (87). 
VPA with doxorubicin appeared to be an effective chemotherapy regimen (16% 
response rate) in patients with refractory or recurrent mesothelioma (88). Vorinostat 
enhanced the efficacy of carboplatin and paclitaxel in patients with advanced non-
small-cell lung cancer (89). One clinical study showed that the combination of 
vorinostat and tamoxifen exhibited encouraging activity in reversing hormone 
resistance of breast cancer (90). The most common side effects of HDAC inhibitors 
are thrombocytopenia, neutropenia, diarrhea, nausea, vomiting and fatigue. Most 
toxicities are not class-specific and have been observed in all HDAC inhibitors (91, 
92). 
 
Recently, new sulforilated compounds, derivated from valproic acid have been 
syntesized by Sulfidris (Milan, Italy). These compounds seem to have a marked 
36 
 
histon-deacetilase activity, with respect to the parental compound valproic acid. 
The release of H2S from this molecole is able to reduce collateral effects of the 
drugs, reducing their cardiotoxicity. Moreover H2S is able to increase the 
pharmacological effect of the drug, increasing the ability to inhibit HDAC (65). 
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2. Aim of the project 
The aim of this project was to analyse the antitumoral activity of two compounds (ACS 2 
and ACS 33), derived from Valproic Acid and conjugated with H2S, in human cancer cell 
lines derived from non-small-cell lung cancer tissues.  
The antitumoral activity of the compounds was analysed together with molecular 
mechanisms of their activity, with the aim to design rationale for combination treatment 
strategy. Different schedules of treatment with conventional chemotherapic drugs were 
tested to identify new potential strategy for the therapy of NSCLC patients.   
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3. Materials and Methods 
Cell lines 
Three human stabilized cell lines derived from lung cancer were used for the different 
studies. In particular: CAEP cell line, isolated and characterized in our laboratory, starting 
from a fresh sample of epidermoidal lung cancer; the commercial Chago K1 cell line, 
derived from a bronchogenic carcinoma; and the commercial NCIH1915 cell line, derived 
from a cerebral metastasis of scarcely differentiated lung carcinoma. Cells were maintained 
in culture in DMEM/HAM F12 (1:1) with the adding of fetal bovine serum (10%), 
glutamine(2 mM), non essential aminoacids (1%) (Mascia Brunelli S.p.A. Milano), and 
insulin (10 µM/ml) (Sigma Aldrich). Cells were used in the exponential phase of their 
growth. 
ACS 2, ACS 33 and Valproic Acid 
ACS 2 compound was solubilized in PEG 400 or DMSO, due to its scarcely solubility in 
aqueous solution. Valproic Acid and ACS 33 compounds were dissolved in DMSO, all at 
concentration of  100 mmol/L. Final concentrations of PEG 400 and DMSO never were 
over 0.5% and 1%, respectively. 
Valproic Acid, ACS 2 e ACS 33 (chemical structures are represented in Figure 1) were 
analysed at concentrations of 1, 35, 70, 140, 210, 280 µM for 72h. Antiproliferative 
activity of the 3 compounds was analysed using sulforodamine B assay (SRB), according 
to Skehan et al. (93). The ability of the compounds to induce apoptosis was analysed by 
TUNEL assay using flow cytometry method.  
 
 
 
 
 
39 
 
 
 
Figure 1. Chemical structures of Valproic Acid, ACS 33 and ACS 2. 
 
 
Drugs combination experiments 
The activity of the ACS 2 compound was evaluated in combination with cisplatin and 
doxorubicin. Different schedules of combination were used. Regarding cisplatin: a) 
simultaneous exposure to ACS 2 compound and cisplatin for 6 hours, followed by ACS 2 
for 66 hours; b) exposure to the sequence ACS 2 for 72 hours, cisplatin for 6 hours, 18 
hours wash out and 72 hours with ACS 2 again; c) inverse sequence, cisplatin for 6 hours, 
18 hours wash out, ACS 2 for 72 hours.  
In these experiments ACS 2 was used at the concentrations of  70, 140, 210, and 280 µM, 
whereas cisplatin at the concentrations of 0.01, 0.1, 1 and 10 µM. Each different 
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experiment was carried out using the different controls (cell line not treated with drugs, 
maintained in culture for the same time expected for samples treated with drugs).  
For combination experiments with doxorubicin: a) doxorubicin exposure for 1 hour, 
followed by 71 hours wash out, and exposure to ACS 2 for 72 hours: b) exposure to ACS 2 
for 72 hours, followed by Doxorubicin for 1 hour, and wash out for 71 hours; c) 
simultaneous exposition to ACS 2 and doxorubicin for 1 hour, followed by exposition to 
ACS 2 for 71 hours. 
In these experiments ACS 2 was used at the concentrations of 70, 140, 210, and 280 µM, 
whereas doxorubicin was used at the concentrations of 0.005, 0.05, 0.5 and 5 µM. 
To analyse the obtained results different methods are present in literature, but some of 
these aren’t applicable to drug with low cytotoxic effect or without a dose-effect curve, as 
in the case of cisplatin. So we choose to use the method of  Romanelli et al. (94).  
In brief, the expected cell survival (Sexp, defined as the product of the survival observed 
with drug A alone and the survival observed with drug B alone) and the observed cell 
survival (Sobs) for the combination of A and B were used to construct an R index (RI): 
RI¼Sexp/Sobs. RI>1.5 indicated a synergistic interaction, RI<0.5, antagonism and 
RI>=0.5 and <=1.5, additivity. 
 
Matrigel invasivity test 
Invasion assays were performed in triplicate in 24-well multiwall plates containing BD 
Falcon Cell Culture inserts with 8-mm filters coated with Matrigel basement membrane 
matrix (BD Biosciences, Milan, Italy). NIH 3T3 cells were used as control cells. After drug 
exposure, each well was loaded with 10 x 104 cells and incubated for 22 h at 37°C in 5% 
CO2 atmosphere. Non-invasive cells were removed from the upper surface of the 
membrane with a cotton swab. The invasive cells on the underside of the membrane were 
fixed in 100% methanol and stained with 1% toluidine blue. The air dried membrane was 
placed on a slide and cells were counted under light microscope at 40 X magnification. The 
percentage of invasion was calculated according to the manufacturer’s instructions. 
 
PCR Real Time 
PCR Real Time was performed for MMP1 and  HPRT1 and GAPDH housekeeping genes 
using TaqMan Gene Expression Assay, and using TAqMan Universal PCR Master Mix, 
No AmpErase UNG (Applied Biosystems, Monza, Italy). PCR reactions were carried out 
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in triplicate on 7500 PCR Real Time System (Applied Biosystems) under the following 
conditions: 95°C for 10 min, and 40 cycles at 95°C for 15 sec and 60°C for 1 min. The 
obtained data were analyzed by AbiPrism 7000 software. Reproducibility of RT-PCR was 
verified in triplicate reactions and the coefficient of variation (CV), calculated from three 
Ct values, was always <1.5%. 
 
Western-blot 
After ACS 2 treatment, cells were lysed in 50 mM di Tris-HCl (pH 8.0), 150 mM di NaCl, 
1% Triton X-100, e 0.1% SDS, with the adding of 1 mM phenylmethylsulfonyl Fluoride 
(PMSF) and a proteases inhibitor cocktail (Sigma-Aldrich). An equal amount of proteins 
were underwent electrophoresis in 12% SDS-poliacrilamide gel. Proteins were transferred 
on a Immobilon-P Transfer Membrane (Millipore). After blockage of aspecific sites, 
membrane was incubated with the specific antibodies: anti-acH3 and anti-acH4 (Upstate 
Millipore, Milan, Italy), and anti-b-actin (Santa Cruz Biotechnology, Inc-DBA., Segrate, 
Italy) as loading control. Densitometric analysis was made using Image Lab software 
(BioRad). 
 
DNA denaturation assay  
DNA denaturability was probed using acridine orange (AO), the metachromatic 
fluorochrome which differentially stains double-stranded (ds) versus single stranded (ss) 
DNA sections (95). AO, when bound to ds DNA, yields green fluorescence, whereas its 
interaction with ss DNA results in red fluorescence (96). The fluorescence color of DNA-
bound AO shows the status of DNA denaturation, which in turn, correlates with chromatin 
condensation. Briefly, cells were fixed with 1% formaldehyde in PBS on ice, then treated 
with RNAse A (MP Biomedicals, 5 Kunitz units/ml) and exposed to 0.1M HCL for 30 sec 
at room temperature. Cells were subsequently stained with AO (10 mg/ml) (Sigma) 
dissolved in 0.1M citric acid-phosphate buffer at pH 2.6. Data were analyzed by flow 
cytometry using a FACSCanto flow cytometer (Becton Dickinson, San Diego, CA) and 
experiments were repeated twice. 
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TUNEL assay 
At the end of drug exposure, the percentage of apoptotic cells was evaluated by flow 
cytometric analysis according to the previously described TUNEL assay procedure (97). 
Briefly, after treatment cells were trypsinized, fixed, exposed to the TUNEL reaction 
mixture, counterstained with propidium iodide, and then analyzed by FACS.  
 
Mitochondrial membrane potential (DC) depolarization assay 
After a 72-h exposure to ACS 2 140 mM, mitochondrial membrane potential was evaluated 
by flow cytometric analysis according to the previously described JC-1 method (97). Data 
acquisition and analysis were performed using CELLQuest software. 15,000 events were 
recorded for each sample. 
 
Cytochrome c release assay 
Cells were treated according to the manufacturer’s instructions (Inno CyteTM Flow 
Cytometric Cytochrome c Release Kit, Calbiochem1, EMD Chemicals, Inc., Darmstadt, 
Germany). Briefly, cells were washed once in PBS and then immediately incubated in 
permeabilization buffer for 10 min on ice, fixed in 8% paraformaldehyde and washed twice 
with 1 X wash buffer. 
Cells were then incubated with anti-cytochrome c antibody diluted 1:1,000 in blocking 
buffer for 1 h, washed and incubated with anti-IgG FITC diluted 1:300 in blocking buffer, 
according to the manufacturer’s instructions. Cells were then resuspended in 1_ wash 
buffer and analyzed using a FACSCanto flow cytometer (Becton Dickinson, San Diego, 
CA). 
 
Statistical analysis 
Differences between treatments in terms of dose-response, apoptosis and gene expression 
modulation were determined using the Student’s t-test for unpaired observations. P<0.05 
was considered significant. 
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4. Results 
Valproic acid didn’t show antiproliferative activity in the examined cell lines. At the 
contrary, the two compounds ACS 2 and ACS 33 showed a cytotoxic activity in all 3 cell 
lines. In particular, ACS 2 was the most active compound, with a growth reduction of over 
50% at concentrations ranging from 64.5 µM and 72 µM (Figure 2) (Table 1). 
Figure 2. Cytotoxic activity of valproic acid and of its derivatives ACS 33 and ACS 2 in 
human lung cancer cell lines ChaGo-K1, CAEP and NCIH1915 after a 72-h exposure. Each 
point indicates the mean of at least three experiments. Standard deviation (SD) never exceeded 
5%. 
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Table 1. Valproic acid, ACS 2 e ACS 33 concentrations able to induce a cell growth 
reduction of 50% in the 3 analysed cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
TUNEL analysis was performed in all 3 cell lines using ACS 2, which showed the higher 
antiproliferative activity. The compound was able to induce apoptosis in all 3 cell lines. In 
particular, 30% of apoptosis was observed in Chago K1 cell line, whereas 60% of 
apoptosis was observed in NCIH1915 and CAEP cells, after treatment with the compound 
at the concentration of 140 µM for 72h (Figure 3). 
 
 
 
 
 
 
Drugs 
 
 
 
IC50 values [µM] 
 
 
ChaGo-K1 
 
CAEP NCIH1915 
 
 
 
  
Valproic 
acid 
n.r.* 
 
n.r. 
 
n.r. 
 
 
ACS33 
 
248 
 
 
n.r. 
 
 
261 
 
ACS2 
 
66,5 
 
 
64,5 
 
72 
 
 
 
  
 
  *not  reached 
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Figure 3. TUNEL analysis 
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At the same conditions (ACS 2 140 µM for 72h) caspase 3 and 9 activation was observed 
(Figure 4), confirming the induction of apoptosis and suggesting a mitochondrial activation 
of the apoptotic process.  
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Figure 4. Western-blot analysis of caspase 3 and 9. 
 
 
The mitochondrial activation of apoptosis was confirmed also by a marked depolarization 
of mitochondrial membrane potential, observed after ACS 2 treatment in all 3 cell lines 
(Figure 5).  
 
Figure 5. Percentage of mitochondrial membrane potential depolarization (DC) after 
a 72-h exposure to ACS 2 140mM. Samples were run in triplicate, and data are the 
average of three experiments. SD never exceeded 5%. 
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In all 3 cell lines an increase of cytocrome c release was observed after treatment with 
ACS 2 (Figure 6).  
 
Figure 6. Cytocrome c release. 
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To test the anti-invasivity capacity of ACS 2, Matrigel analysis was performed on 
NCIH1915 cell line. After treatment with the compound for 72h at the concentration of  
140 µM, the invasion capacity of cells decreased of about 30% (Figure 7). 
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Figure 7. Invasivity test on NCIH1915 cells after exposure to ACS 2. 
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The reduction of invasive capacity of cells was accompanied by a reduction of expression 
levels of MMP 1, protein involved in the process of invasion and metastatization       
(Figure 8). 
 
Figure 8. Expression levels of MMP1 analysed through Real Time PCR, and using as 
housekeeping genes HPRT1 and GAPDH. 
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The ability of ACS 2 to interfere with the denaturation process of DNA, and as 
consequence with chromatin condensation grade, was also analysed. This search was 
finalized to found a rationale to combine ACS 2 compound with chemotherapic drugs with 
the ability to induce DNA damage, with the aim to design specific drug combination 
schedule of treatment.  First of all the expression levels of the acetylated form of two 
histonic proteins, H3 e H4, was analysed in CAEP cell line. An increase of 1.61 and 1.58 
fold in the expression level of  ac-H3 e ac-H4, respectively, was found after 4 h exposure 
to ACS 2 at the concentration of 140 µM, with respect to control (Figure 9). 
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Figure 9. Expression levels of acetilated form of H3 e H4 histones, evaluated by 
Western-blot. 
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To confirm these findings, we used the acridine orange (AO) assay to analyze the different 
grades of susceptibility to denaturation of CAEP cells after exposure to ACS 2 140mM. 
Such an approach takes advantage of the fact that DNA in extended rather than condensed 
chromatin differs in susceptibility to denaturation, which in turn, correlates with chromatin 
condensation grades. Once again, we observed an increment of up to 30% in AO bound to 
ssDNA with respect to ds DNA, which is symptomatic of chromatin decondensation 
(Figure 10). Similar results were obtained in ChaGo-K1 and NCIH1915 lines (data not 
shown). 
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Figure 10. Orange acridine assay. 
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ACS 2 was then analysed in combination with cisplatin. The activity was different in 
relation to the different schedules of treatment.  In particular, the sequence cisplatin for 6h, 
wash out 18h, ACS 2 72h showed an additive effect in NCIH1915 and CAEP cell lines, 
whereas showed an antagonistic effect in ChaGo-K1 cells. The inverse combination, ACS 
2 72h followed by cisplatin for 6h and 18h of wash out resulted in an additive effect in all 
cell lines. 
Conversely, a strong synergistic interaction was observed when ACS 2 and cisplatin were 
administered together. (Table 2 and Figure 11). 
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Table 2. Interaction between ACS 2 and cisplatin. 
 
 
Figure 11. Synergistic interaction between ACS 2 and Cisplatin used simultaneously 
(ACS 2 + cisplatin for 6h followed with ACS 2 for further 66h). 
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Moreover, the combination of ACS 2 with doxorubicin was also analysed, and all 
treatment schedule showed an additive results (Table 3). 
 
Table 3. Interaction between ACS 2 and doxorubicin 
 
DRUG SCHEDULE INTERACTION TYPE NCIH 1915 CAEP CHAGO-K1 
 
DOXO (1h)→ 72h w.o. → ACS (72h) 
 
 
additive 
 
 
additive 
 
additive 
 
ACS (72h) → DOXO (1h)→ 72h w.o. 
 
 
additive 
 
 
additive 
 
additive 
 
ACS + DOXO (1h) → ACS (72h) 
 
 
 additive 
 (RIm*= 1.5) 
 
additive 
 
 
additive 
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5. Discussion 
 
Histone deacetylases (HDACs) are a family of enzymes that regulate chromatin 
remodeling and gene transcription, and there is growing interest in HDAC inhibitors as 
promising anticancer agents. Short chain fatty acids such as butyric and valproic acid were 
the first HDAC inhibitors to be identified as tumor growth inhibitors and inducers of 
apoptosis both in vitro and in vivo. However, they were found to have low potency, with 
IC50 in the millimolar range. Despite such weak in vitro activity, VPA’s anticancer 
mechanism of action has been investigated in preclinical models of skin, breast, colon, 
prostate and small cell lung cancer, and the drug is currently used in phase I–III clinical 
trials (98, 99). Unfortunately, therapeutic doses of VPA are necessarily very high and 
cause limiting side-effects. An attempt to overcome the weak potency of VPA, due mainly 
to its inability to access the zinc cation in the HDAC active-site pocket, has been made by 
inserting sulfurated groups, selected amongst those known to be endowed with cancer 
chemopreventive activity and described as potent HDAC inhibitors, in the valproate 
moiety (100- 102). 
In this study we evaluated the antitumor activity of valproic acid and its derivatives ACS 
33 and ACS 2 bearing a thiosulfonate and dithiolthione moiety, respectively, in a panel of 
NSCLC cell lines. Both derivatives exhibited a much higher cytotoxic activity than that of 
the parent compound, with ACS2 proving to be the most effective drug, capable of 
reducing cell survival by 50% in all cell lines tested and at low concentrations. 
Such data are in agreement with those reported by Moody et al. (103), although it must be 
pointed out that these authors used different cell lines and cell survival assays. The 
possibility of using ACS 2 at low concentrations has therapeutic implications as it would 
eliminate the problem of side-effects of the valproate component, making ACS 2 a 
potential ‘‘lead’’ compound for clinical development. On the basis of these data, we 
investigated the mechanism of action underlying the improved antitumor effect of ACS 2 
with respect to the parent compound, and discovered that the strong cytotoxic activity of 
ACS 2 is largely due to its pro-apoptotic action observed in all cell lines. Our findings also 
showed that ACS 2 triggers apoptotic machinery via the mitochondrial pathway, as 
highlighted by the strong mitochondrial membrane depolarization, cytoplasmatic 
cytochrome c release and caspase-9 and -3 cleavage. These data differ from the results 
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obtained by Moody and coworkers who did not register apoptosis after exposure of NCI-
H1299 cells to ACS 2. Such a difference can probably be attributed to the specific 
experimental conditions used by the authors, i.e., the short exposure time (24 h) and the 
lower drug concentration (28mM) (103). 
Matrix metalloproteinase-1 (MMP-1), an interstitial collagenase, plays an important role in 
the breakdown of extracellular matrix and mediates pathways of apoptosis, angiogenesis, 
and immunity. It has also been demonstrated that the overexpression of this enzyme is 
associated with tumor initiation, invasion, and metastasis of many types of human cancer 
including lung cancer (104-106). Furthermore, a specific polymorphism of MMP-1 (MMP-
1-1607 1G-to-2G) was recently found to be associated with susceptibility to both growth 
and progression  of lung cancer (107). In our study, we showed that ACS 2 significantly 
reduces cell survival, diminishes the invasive capacity of NCIH1915, an established cell 
line obtained from a metastatic brain lesion, and downregulates MMP-1 expression. These 
data, together with the anti-angiogenic activity described by Isenberg et al. (108), highlight 
the potential therapeutic effectiveness of ACS 2 in advanced NSCLC where patient 
survival is very poor due to the high incidence of metastases. Conventionally, NSCLC is 
treated with surgery in its early stages, while combination chemotherapy consisting of 
platinum-based regimens is standard practice in advanced disease. In our study we 
explored the potential for using ACS 2 in combination with cisplatin and aimed to design 
an effective schedule based on the plasmatic half-life of both drugs. Our findings show that 
the simultaneous use of ACS 2 and cisplatin for 6 h followed by a further 66-h exposure to 
ACS 2 produced a highly tumoricidal effect in all cell lines tested starting from the lowest 
doses of both drugs. Furthermore, renal protection against the effect of cisplatin afforded 
by another dithiolethione (109), in addition to the possibility of using low doses of both 
drugs, highlights a potentially good safety profile of the drug schedule. Finally, it can be 
hypothesized that the synergism between the two drugs is ascribable to the effect of ACS2 
on chromatin remodeling through HDAC inhibition, which makes DNA less compact and 
more sensitive to cisplatin induced damage. In fact, lower chromatin condensation was 
confirmed when an increase in acetylation of the two core histonic proteins (H3 and H4) 
was detected, a hallmark of chromatin relaxation, after a short exposure to ACS 2. We also 
observed an increase in DNA susceptibility to denaturation after the same exposure time, 
which in turn correlates with chromatin decondensation (95). 
Doxorubicin, a widely used antiblastic agent, is considered ineffective against a number of 
tumor types, including NSCLC, because of its narrow therapeutic range, outside of which 
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side effects such as severe cardiotoxicity have been observed (110, 111). A recent study 
has shown that deficiencies in H2S synthesis may contribute to the pathogenesis of 
doxorubicin-induced cardiomyopathy and that administration of NaHS, an H2S donor, 
ameliorates doxorubicin-related cardiac dysfunction by inhibiting oxidative stress injury 
(112). The use of H2S donors could therefore prove to be a promising therapeutic strategy 
to prevent doxorubicin-induced cardiotoxicity. We thus attempted to define an effective 
drug schedule for ACS 2 and doxorubicin in our preclinical models, observing an additive 
interaction independently of the combination scheme used. These preliminary data are 
nevertheless interesting because of the potential cardiovascular protection provided by the 
H2S component of ACS 2. Further research is warranted into this specific area. 
In conclusion, our findings, in addition to demonstrating the increased cytotoxic activity of 
ACS 33 and ACS 2 with respect to valproic acid, highlight the strong pro-apoptotic 
activity of ACS 2, a promising lead compound of this new class of HDAC inhibitors. 
Furthermore, we identified a highly effective combination schedule of ACS 2 and cisplatin 
capable of inducing a synergistic interaction even when the two drugs are used at low 
concentrations. This increased efficacy is probably due to the modification induced by the 
valproate derivative on chromatin condensation, facilitating the establishment of cisplatin-
DNA abducts. For these reasons, the VPA derivative ACS 2 in combination with platinum 
compounds could represent a promising alternative to traditional chemotherapeutic 
regimens used for advanced lung cancer. 
Further in vivo studies are needed to confirm these results. 
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